Gain Therapeutics (GANX) Receivables - Other (2022 - 2023)
Gain Therapeutics (GANX) posted quarterly Receivables - Other of $33261.0 for Q1 2023, down 64.94% year-over-year from $94863.0 in Q1 2022, and down 61.96% quarter-over-quarter from $87430.0 in Q4 2022.
Gain Therapeutics (GANX) Receivables - Other (2022 - 2023) Analysis & Trends
Gain Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $33261.0 for Q1 2023.
- In Q1 2023, Receivables - Other fell 64.94% year-over-year to $33261.0; the TTM figure through Mar 2023 stood at $33261.0 (down 64.94% YoY), while the FY2022 annual figure was $87430.0, up 6.8% from the prior year.
- Receivables - Other for Q1 2023 stood at $33261.0, down from $87430.0 in the prior quarter.
- The five-year high for Receivables - Other was $101916.0 in Q3 2022, with the low at $33261.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 33,261.00 |
| Mar 31, 2023 | 33,261.00 |
| Dec 31, 2022 | 87,430.00 |
| Dec 31, 2022 | 87,430.00 |
| Sep 30, 2022 | 101,916.00 |
| Sep 30, 2022 | 101,916.00 |
| Jun 30, 2022 | 95,993.00 |
| Jun 30, 2022 | 95,993.00 |
| Mar 31, 2022 | 94,863.00 |
| Mar 31, 2022 | 94,863.00 |